Labcorp’s New Alzheimer’s Blood Test Might Change The Case For Investing In Labcorp Holdings (LH)

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...
Seeking Alpha

Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology

Rules out Alzheimer's pathology in early stages to enhance diagnostic pathway efficiency Provides new opportunity to broaden access and improve referral quality Features as part of Roche's growing ...
Indianapolis Monthly

The Creation Of An Alzheimer’s Detection Test

A new diagnostic test developed by Indianapolis medical giants can help identify or rule out Alzheimer’s in patients with ...
Medindia

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...
Yahoo

Roche’s Genentech present data on trontinemab, Elecsys plasma test

Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/arch-biopartners-appoints-patrick-vink-as-chairman-of-the ...
WMUR

FDA clears blood test to help rule out Alzheimer’s disease in people showing symptoms

The U.S. Food and Drug Administration has given clearance to another blood test to help assess Alzheimer’s disease and other causes of cognitive decline, providing a broader understanding of when the ...